Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Studie RHINO (Rinovirová hospitalizace a výzkum nosních-dýchacích cest omiky)

10. listopadu 2026 aktualizováno: University of Wisconsin, Madison

Identifikace zátěže hospitalizace způsobené rhinovirem (RV) u dětí a mechanismů patogeneze pomocí molekulárního profilování dýchacích cest

The goal of this study is to determine the burden of Rhinoviruses (RVs) as a cause of acute, severe, respiratory illnesses leading to hospitalization. A community cohort of 120 children between 12 and 36 months of age will be enrolled in the first year of the study and followed (when well and sick) for 36 months to identify the circulating RVs and provide samples to establish a host nasal transcriptome differentiating clinical from subclinical RV infections. A hospitalized cohort of 450 infants and children will be enrolled during years 1 through 3 of the study and followed for the duration of their hospitalization to investigate the findings of the community cohort. An additional 100 healthy children aged 5-17.5 years will be enrolled for age-match comparison with the older hospitalized cohort.

Přehled studie

Detailní popis

Aim 1: Involves the prospective creation of a cohort of generally healthy children 12 to 36 months to be followed longitudinally for 36 months in an observational study. To determine the frequency of virus infection with RV and other respiratory viruses, children will have two swabs of the nasal mucosa performed whenever they develop an acute respiratory illness (upper respiratory symptoms lasting more than 24 hours) and four times a year for surveillance. One swab will be of the anterior nose and will be used for identification of viruses, and a second mid-turbinate swab will be used for host transcriptomics. This will allow the investigators to create many samples from both symptomatic and asymptomatic infections. The samples will be used to develop a host signature to discriminate symptomatic and asymptomatic infection.

Aim 2a: Involves the evaluation of generally healthy children hospitalized at AFCH with acute, lower respiratory tract infections including bronchiolitis, asthma, acute hypoxemic respiratory failure and community acquired pneumonia. There will also be the evaluation of infants less than 6 months of age who may become ill with an RV syndrome. These children will be evaluated with two nasal swabs as above. This allows the identification of children infected with RV and other respiratory viruses. Application of the host signature developed in Aim 1 will determine the actual proportion of those children who are infected with RV whose illness (clinical symptoms) is caused by RV.

Aim 2b: Involves the prospective creation of a cohort of generally healthy children 5 to 17.5 years old to be sampled on an as-needed basis to serve as age- and season-matched controls for the Hospitalized Group. To determine the frequency of virus infection with RV and other respiratory viruses, 2 healthy children will provide a single swab of the nasal mucosa within 2 weeks of each hospitalized participant who is 5-17.5 years of age. The one swab will be of the anterior nose and will be used for identification of viruses. Age matching will occur within 3 groups:

  • Ages 5-8 years old: n=50
  • Ages 9-13 years old: n=30
  • Ages 14-17.5 years old: n=20

Aim 3: Use parallel bulk and single cell RNA sequencing (scRNA-seq) to identify targetable processes of acute, severe LRT caused by RV. The investigators hypothesize that integrated bulk RNA-sequencing and scRNA-seq will identify immune/inflammatory defects and targets for intervention. Bulk and scRNA-seq on respiratory samples from well-characterized patients with severe RV disease will be performed to test this hypothesis and to compare samples obtained from those with non-severe disease.

Typ studie

Pozorovací

Zápis (Odhadovaný)

670

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Wisconsin
      • Madison, Wisconsin, Spojené státy, 53792
        • Nábor
        • University of Wisconsin

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

Ne starší než 17 let (Dítě)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

Aim 1: Generally healthy male and female children 12 to 36 months of age living in Dane County and surrounding areas representative of the general demographics of the county.

Aim 2a: Hospitalized male and female children between newborn and 17.5 years of age with acute onset lower respiratory tract infections. These children will span all demographic and socioeconomic groups.

Aim 2b: Generally healthy male and female children 5 to 17.5 years of age living in Dane County and surrounding areas representative of the general demographics of the county.

Popis

Inclusion Criteria (Aim 1 and Aim 2b Community Groups):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Willing to comply with all study procedures and be available for the duration of the study.
  • Younger Community Group: Generally healthy children 12 to 36 months of age at the time of enrollment
  • Older Community Group: Generally healthy children 5 to 17.5 years of age at the time of enrollment.
  • Current patient within primary care system at UW Health

Inclusion Criteria (Aim 2a: Hospitalized Group):

  • Parent/legal guardian is willing and able to provide informed consent in English.
  • Admitted to American Family Children's Hospital (AFCH) within the past 24 hours or have been assigned an admission-related status (including "Admit Probable" or "IP Bed Requested") that reflects an expected inpatient admission.
  • Children under 17.5 years of age at the time of enrollment
  • Has a diagnosis of bronchiolitis, asthma exacerbation, acute hypoxemic respiratory failure or community acquired pneumonia (CAP) OR is an infant less than 6 months of age with fever greater than 38 degrees Celsius within 24 hours of hospital admission

Exclusion Criteria (all participants):

  • Congenital or currently acquired immunosuppressive condition or medications (e.g., congenital immunodeficiency, Leukemia, Lupus)
  • Congenital anomalies that might alter frequency of infection (e.g., unrepaired cleft palate, bronchial cyst, pulmonary sequestration)
  • Presence of tracheostomy or gastrostomy tube
  • Previously enrolled a different group in the study
  • Other child in the same household already enrolled in the study
  • Not suitable for study participation due to other reasons at the discretion of the investigators.

Exclusion Criteria (Aim 1: Community Group Only):

  • History of chronic pulmonary diseases (e.g., asthma, cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma IS exclusionary), reactive airway disease within the Older Community Group is not exclusionary unless they have a maintenance inhaler.
  • Acute upper respiratory symptoms within the past week (7 days) at the time of enrollment

Exclusion Criteria (Aim 2: Hospitalized Group Only):

  • History of chronic pulmonary diseases, excluding asthma (e.g., cystic fibrosis, bronchopulmonary dysplasia (BPD)) (Note: asthma is NOT exclusionary)
  • A positive test for any other respiratory virus other than RV within the 48 hours prior to and including admission documented at the time of consent. (Note: Negative for rhinovirus is not exclusionary).
  • Non-respiratory infection at the time of admission (e.g. Bacteremia) (Note: UTI, Osteomyelitis, Otitis media, and MRSA colonization is not exclusionary.)
  • Uncontrolled and/or profound neurologic disease, as determined by the investigator or designee at time of admission, considering factors such as uncontrolled seizures, inability to ambulate, inability to communicate verbally, or dependence on a gastrostomy tube (G-tube) or ventilatory assistance (e.g., positive pressure ventilation) (e.g., cerebral palsy, genetic neurologic diseases).

Exclusion Criteria (less than 5 years old only (All participants in Aim 1 and some participants in Aim 2a):

  • Born prematurely, less than 32 weeks 0 days gestational age

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
Younger Community Cohort (12-36 months of age)

Quarterly Surveillance Nasal Swabs and Nasal Swabs targeted around respiratory symptoms for up to 36 months of age, participants will provide one anterior and one mid-turbinate nasal swab sample

Families will be asked to collect nasal swabs from their children during specified surveillance months (February, April, September, and December). Caregivers will be instructed to only collect surveillance samples during these months if and when children have been free of respiratory symptoms for at least two weeks prior to sampling. Caregiver surveys are part of quarterly surveillance.

Caregivers will be instructed to watch for respiratory symptoms and collect nasal swabs 24-48 hours after symptom onset. Caregiver surveys are part of sick sample collection

Caregivers are surveyed 7-13 days after sick sample collection

Hospitalized Cohort of Infants and Children

Generally healthy infants and children hospitalized for respiratory illness will provide one anterior and one mid-turbinate nasal swab sample

2 nasal swabs collected upon consent, one anterior and one mid-turbinate

For hospitalized participants who opt to induce sputum, 3 medications will be used to obtain the sample, albuterol sulfate solution and hypertonic saline (3% solution) administered via nebulizer and and lidocaine spray (4% solution) via atomizer to the nose. For hospitalized participants with pneumonia who opt for research blood draw or induced sputum, optional administration of oral sucrose (Sweet-Ease) may occur at the discretion of the treating provider.

Ostatní jména:
  • Hypertonický fyziologický roztok
  • Sweet-Ease
  • Lidokainový sprej
  • Albuterol sulfate solution
Older Community Cohort (5 to 17.5 years of age)

Age-matched controls for older children in the Hospitalized Group, will be called upon as needed based on enrollment of hospitalized patients

Participants will be enrolled as needed based on enrollment of hospitalized patients

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Cíl 1: Unikátní nosní transkriptomický podpis klinických infekcí rinovirem
Časové okno: data collected up to 36 months
data collected up to 36 months
Aim 1: Summary of Rhinovirus Types Identified in Community Cohort
Časové okno: data collected up to 36 months

To test study hypotheses, the study team will identify the circulating RV types in symptomatic and asymptomatic children.

data collected up to 36 months

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Aim 2: Summary of Rhinovirus Types Identified in lower respiratory tract (LRT) infections and upper respiratory tract infections (URI), Reported as Percent in Common
Časové okno: data collected up to 36 months

To test the hypothesis that there will be an 80 percent overlap between RV types causing acute LRT and URI, investigators will compare all RV types identified in age-matched hospitalized and ambulatory children.

data collected up to 36 months
Aim 2: Proportion of Hospitalized Cohort with lower respiratory infections attributable to Rhinovirus
Časové okno: data collected up to 36 months

The investigators will use host nasal transcriptomics derived from symptomatic and asymptomatic children with RV infection to determine the proportion of age-matched hospitalized LRT infections actually attributable to RV.

data collected up to 36 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Ellen R Wald, MD, UW School of Medicine and Public Health

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

4. srpna 2026

Primární dokončení (Odhadovaný)

1. května 2030

Dokončení studie (Odhadovaný)

1. května 2030

Termíny zápisu do studia

První předloženo

13. ledna 2026

První předloženo, které splnilo kritéria kontroly kvality

13. ledna 2026

První zveřejněno (Aktuální)

15. ledna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

13. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2025-1076
  • SMPH\PEDIATRICS\INFECT DIS (Jiný identifikátor: UW Madison)
  • 1R01AI182200-01A1 (Grant/smlouva NIH USA)
  • Protocol Version 8/25/26 (Jiný identifikátor: UW Madison)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

This study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-funded research that generates large-scale human or non-human genomic data, as well as the use of these data for subsequent research. Large-scale data include genome-wide association studies (GWAS), single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and gene expression data.

Časový rámec sdílení IPD

Data from this study may be requested from other researchers 3 years after the completion of the primary endpoint by contacting the study team at UW-Madison.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit